INTRODUCTION
The etiology of many cancers, especially those involving multiple genes or sporadic mutations, remains unknown. Expressed sequences (mRNA and ESTs [1] ) from various normal or cancer tissues and cell lines have been accumulated in public sequence databases. This wealth of EST information, though a majority of it comes from heterogeneous cell types of different tissues, captures some of the changes inherent in carcinogenesis. We attempted to identify some of these changes through computational analysis of EST clustering and EST tissue information. Several earlier studies have examined EST tissue information. Counting the number of ESTs in UniGene clusters [2] , with or without rigorous probability calculation [3] , was used to identify endothelium-specific genes [4] , disease-specific or tissue-specific polyadenylation sites [5] , colon cancer-related genes [6] , and genes differentially expressed in normal or cancer tissues [7, 8] , and to build tissue expression profiles for adult skeletal muscle [9] and retina [10] . ESTs from well-defined tissue sources were used to construct a sophisticated BodyMap [11] . However, all of these published approaches failed to consider alternative splicing-estimated to occur in over 50% of human genes [12] [13] [14] [15] -because UniGene clusters do not have multiple alignments. In addition, ESTs in these studies were restricted to those from non-normalized libraries. SAGE [16, 17] and microarray experiments [18] have been used extensively to study gene expression, but these methodologies must be linked with alternative splicing modeling to be of use for investigating alternative splicing. 
RESULTS AND DISCUSSION
Human EST and mRNA sequences were aligned against genomic sequences and clustered through Compugen's LEADS platform [19] [20] [21] [22] , which identified the boundaries of introns and predicted alternative splicing sites (Fig. 1) . Modeling of alternative splicing has been reported with different degrees of sophistication [14, 23, 24] . The 20,301 clusters with 2.0 million ESTs contained at least one mRNA sequence, in general agreement with UniGene build #148 with 20,876 mRNA-containing clusters. The remaining EST sequences were clustered to unknown regions of known genes or to unknown genes. These ESTs were not analyzed. Fig. 1 ). Table 2 lists some statistics of alternative splicing events based on this simplification. We analyzed tissue information of ESTs in this cohort of clusters. Table 3 lists the 10 tissue types with the largest numbers of ESTs along with those from pooled or uncharacterized tissues. An alternative splicing event has at least two donor-acceptor concatenations. In more than half of the cases, concatenations between donor (exon A; Fig. 1 ) and proximal acceptor (exon B) and between acceptor (exon C) and proximal donor (exon B) are supported by a higher number of EST libraries than those between donor (exon A) and distal acceptor (exon C) and between acceptor (exon C) and distal donor (exon A). This result indicates that exon skipping is not prevalent. Very few concatenations (three in prostate, one in lung, and one in placenta) [25] supported by ESTs from more than four libraries were restricted to a single tissue type, suggesting that the absolute tissue-specific alternative splicing might be rare among the genes analyzed. The non-quantitative nature of the current analysis method precludes the identification of alternative splicing events that are tissue-specific, yet are not restricted to a single tissue type. In these few cases, the whole genes tend to be tissue-specific, some of which have been regarded as tissue markers, and those identified events may serve as more specific tissue and diagnostic markers, as   FIG. 1 . Schematic representation of LEADS alignment and alternative splicing with three exons (A, B, C) and two introns (1, 2) . ESTs and mRNAs were aligned to the genome and the splicing junctions were determined through the alignments. Two alternative splicing events are distinguished here. One, from the donor site, involves AB (between donor and proximal acceptor) and AC (between donor and distal acceptor), and the other, from the acceptor site, involves AC (between distal donor and acceptor) and BC (between proximal donor and acceptor). suggested earlier [26] . For example, the short form of a prostatespecific protein, PSP57 [27] , resulted from the concatenation of exon 2 and exon 4, which is supported by ESTs from 11 prostate libraries, whereas in the long form, PSP94, concatenations of exons 2, 3, and 4 were supported by ESTs from six types of tissues. We tried to identify discordant (or mutually exclusive) expressions of alternatively spliced transcripts, where the transcripts are expressed in non-overlapping sets of tissues. For that purpose, we examined alternative splicing events with only two concatenations, each of which was supported by ESTs from at least five libraries, where the two concatenations were supported by ESTs from different tissues. Six acceptor sites and seven donor sites have been identified [25] . As an example, in the gene XRCC3, the first 36 bp, the next 57 bp, and the subsequent 102 bp belong to three exons (here named A, B, and C).
The concatenation of exon A to exon C is supported by mRNA sequence BC011725 and ESTs from five libraries originating from lymph node, cervix, muscle, mammary gland, and eye. The concatenation of exon B to C is supported by multiple mRNA and ESTs in nine libraries from nervous system, placenta, uterus, gastrointestinal tract, kidney, and pancreas. Cell heterogeneity of most tissues in EST databases precludes the identification of cell type-specific alternative splicing. We examined alternative splicing events that are restricted to cancer tissues by looking for any donor-acceptor concatenations exclusively supported by ESTs from cancer tissues. Table 4 lists six interesting examples [25] . The gene NONO with BC003129 and 1496 ESTs encodes a possible splicing factor, suggesting that alternative splicing of multiple genes may be regulated during carcinogenesis. Lack of a complete and accurate inventory of transcripts hinders the identification of transcripts that are highly expressed in particular cancer tissues. However, the EST clustering and tissue information analyses can be used to identify specific gene segments that are highly represented in cancer tissues. We ranked all gene segments with probability scores and identified several possible colon cancer markers [25] (Table 5 ). Gene segments highly expressed in other tissues or other types of cancers can be identified similarly. During a selection of 200 gene segments for lung cancer markers, several recently published lung cancer markers [28, 29] , including AA033947, AA600214, AA664179, H58872, X53463, M11507, and X01060, were identified. With systematic classification of histology and oncology, such as Gene Ontology [30, 31] , sufficient numbers of sequences from homogenous cells, and accurate and detailed descriptions of tissue sources and library construction, the approach outlined here may identify some of the genetic alterations in carcinogenesis. One of the mRNAs, or one of the ESTs if no mRNA contains both splicing junctions, is listed to identify the cluster. Under the "Type" column, the designation from either the donor site (d) or acceptor site (a) and to either the proximal (+) or distal (-) exon indicates the type of transcript shown to be cancer-specific. For example, "d+" indicates AB (Fig. 1) is cancer-specific. In cases of exon skipping or intron retention, the cognate donor site and acceptor site showed same or similar profile. Please note: under the "Total" column the number of ESTs or mRNAs is listed. Under "Specific" or "Nonspecific" columns, the library count is listed. All mRNA sequences under "Specific" are from cancer tissues, and there were no normal ESTs under "Specific." The numbers under the "Position" column identify the splicing junctions on the mentioned sequence.
MATERIALS AND METHODS
DATA and LEADS alternative splicing modeling. GenBank version 125 with genomic build #25 from the National Center for Biotechnology Information (NCBI) was input to the LEADS platform as described [19] [20] [21] [22] . The LEADS process aligned about 80,000 mRNA and 3.7 million ESTs with genomic sequences. The mRNAs and ESTs supporting any expressed genomic segment or donor-acceptor concatenations were identified. Results from the application of the LEADS platform have also been reported [19] [20] [21] [22] . UniGene Build #146 and libraryQuest.txt were obtained from the NCBI and Cancer Genome Anatomy Project (CGAP) and the National Cancer Institute (NCI), respectively.
EST tissue information.
Most ESTs have tissue library information. The information is also available in web form in Library Browser or Library Finder in NCBI or in the flat file libraryQuest.txt. The file lists 53 tissue sources, five histological states (cancer, multiple histology, normal, pre-cancer, and uncharacterized histology), six types of tissue preparations (bulk, cell line, flow-sorted, microdissected, multiple preparation, and uncharacterized), and brief descriptions for each library. The ORESTES set with 5000 libraries has close to one million ESTs [32] . The 5318 libraries were from bulk tissue preparation (including 5000 ORESTES libraries), 329 were from cell lines, 37 were flow-sorted, 66 were microdissected, 5 were multiple preparations, and 1121 were from uncharacterized preparations. Excluding ORESTES libraries, 507 libraries were designated as "non-normalized" and 100 were designated "normalized" or "substracted" indicating the pretreatment of mRNA before cDNA library construction. A small number of libraries were derived from the same original sample. They were not considered separately. Library counts of ESTs rather than direct EST counts are used to provide semi-quantitative measurements of expression level, as EST counts in some cases reflect the prevalence of ESTs in one or a few particular libraries, and library counts provide better indications across different tissue types when both normalized and non-normalized libraries were analyzed. Such tissue information analyses are limited to those tissues with a sufficient number of libraries. The inclusion of normalized cDNA libraries allowed the examination of genes expressed at low levels.
To exclude possible genomic contamination in expressed sequences and other EST problems, only donor-acceptor concatenations or gene segments aligned with at least one mRNA or ESTs from at least two libraries were considered. The ESTs from "pooled tissue" or "uncharacterized tissue" were considered non-conforming in order to maintain the robustness of the results. In addition, 139,243 ESTs that had no library information were considered nonconforming in investigating tissue-or cancer-specific alternative splicing events, and were not considered in gene segment selection.
Simple probability scoring based on the binomial distribution was used to rank gene segments highly expressed in particular tissues. In the case of colon cancer (Table 5) , the colon tumor library number, the colon library number, and the total library number for each gene segment were considered.
Supplementary data for this article are available on IDEAL (http://www. idealibrary.com).

